Table 1.
Characteristics of included trials (n = 228)
| Characteristic | Trials, No. (%) |
|---|---|
| Trial phase | |
| II | 32 (14.0) |
| II/III | 17 (7.5) |
| III | 151 (66.2) |
| Other | 28 (12.3) |
| Recruitment regions* | |
| United Kingdom | 221 (96.9) |
| Spain | 65 (28.5) |
| Italy | 63 (27.6) |
| Canada | 62 (27.2) |
| France | 62 (27.2) |
| Germany | 58 (25.4) |
| United States | 55 (24.1) |
| Belgium | 54 (23.7) |
| Australia | 51 (22.4) |
| Poland | 47 (20.6) |
| Russian Federation | 43 (18.9) |
| Netherlands | 41 (18.0) |
| Korea, Republic of | 34 (14.9) |
| Brazil | 30 (13.2) |
| Austria | 29 (12.7) |
| Sweden | 29 (12.7) |
| Argentina | 28 (12.3) |
| Israel | 28 (12.3) |
| Czech Republic | 26 (11.4) |
| Hungary | 25 (11.0) |
| China | 24 (10.5) |
| Japan | 24 (10.5) |
| Taiwan | 24 (10.5) |
| Turkey | 24 (10.5) |
| Cancer type | |
| Breast | 37 (16.2) |
| Lung | 28 (12.3) |
| Prostate | 21 (9.2) |
| Colorectal | 15 (6.6) |
| Ovarian | 14 (6.1) |
| Other | 115 (50.4) |
| Source of funding† | |
| Industry only | 79 (34.6) |
| Public only | 34 (14.9) |
| Charity only | 85 (37.3) |
| Mixed | 30 (13.2) |
| PRO | |
| Primary outcome | 42 (18.4) |
| Secondary outcome only | 186 (81.6) |
| Both | 28 (12.3) |
| PROs measured | |
| Quality of life | 163 (71.5) |
| Symptom burden | 128 (56.1) |
| Anxiety and depression | 24 (10.5) |
| Other | 12 (5.3) |
| PRO questionnaires used | |
| EORTC QLQ-C30 | 95 (41.7) |
| EQ-5D | 54 (23.7) |
| HADS | 21 (9.2) |
| Other | 92 (40.4) |
| Year of trial closure | |
| 2001 | 2 (0.9) |
| 2002 | 5 (2.2) |
| 2003 | 4 (1.8) |
| 2004 | 3 (1.3) |
| 2005 | 12 (5.3) |
| 2006 | 9 (3.9) |
| 2007 | 8 (3.5) |
| 2008 | 20 (8.8) |
| 2009 | 23 (10.1) |
| 2010 | 32 (14.0) |
| 2011 | 34 (14.9) |
| 2012 | 34 (14.9) |
| 2013 | 38 (16.7) |
| 2014 | 4 (1.8) |
Additional recruitment regions included in less than 10% of trials: Greece, Switzerland, New Zealand, Ireland, Mexico, Singapore, Hong Kong, India, Thailand, Denmark, Romania, Portugal, South Africa, Finland, Chile, Norway, Peru, Slovak Republic, Ukraine, Bulgaria, Colombia, Croatia, Estonia, Puerto Rico, Philippines, Latvia, Egypt, Guatemala, Luxembourg, Panama, Serbia, Slovenia, Bosnia and Herzegovina, Costa Rica, Cyprus, Lebanon, Lithuania, Malaysia, Saudi Arabia, Bahamas, Belarus, Ecuador, Indonesia, Macedonia, Pakistan, Tunisia, and Uruguay. See Supplementary Appendix (available online) for additional information. EORTC QLQ = European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; EQ-5D = EuroQol Five Dimension preference-based health status measure; HADS = Hospital Anxiety and Depression Scale; NIHR = National Institute for Health Research; PRO = patient-reported outcome.
As listed on the NIHR Portfolio Database.